Elicio Therapeutics Shares Plunge 72% After Pancreatic Cancer Vaccine Misses Mid-Stage Trial Goal

Shares in Elicio Therapeutics (ELTX) fell roughly 72% after the biotech company's experimental pancreatic cancer vaccine failed to meaningfully extend the time patients lived without disease recurrence, missing the primary endpoint of a mid-stage clinical study.

The therapy, ELI-002 7P, is designed to deliver treatment directly to the lymph nodes in order to stimulate immune responses against cancer cells carrying mutations in the KRAS gene — one of the most common drivers of pancreatic cancer. The trial enrolled 144 patients who had undergone surgery and standard treatment and were free of detectable disease at the point of enrollment.

Elicio attributed part of the shortfall to an imbalance in residual disease between the two groups: approximately 19% of patients who received the treatment carried higher levels of residual disease at baseline — raising their risk of relapse — compared with around 10% in the control arm. The company said this disparity likely weighed on the results.

Mayank Mamtani, an analyst at B. Riley, noted that the trial bore the added burden of generating the first randomized efficacy data for a KRAS-targeted cancer vaccine, and that its broad enrollment criteria, which did not screen out patients by residual disease burden, "may have blunted the detectable treatment effect." He added that the case for continued development now rests on a later-stage study focused on patients with lower residual disease and evaluating additional dosing regimens.

In a subset of patients who had achieved complete surgical clearance of cancer — representing approximately 84% of the study population — the therapy produced an average disease-free survival of 23.8 months, compared with 12.8 months in the control arm, which received standard of care alone. The treatment also showed a favorable safety profile, with no treatment-related discontinuations and a lower rate of adverse events than the control group, which Elicio said supports its potential for long-term use and combination approaches.

Unlike the personalized mRNA cancer vaccines being developed by Moderna (MRNA) in combination with Merck's (MRK) blockbuster immunotherapy Keytruda — which must be custom-manufactured for each individual patient based on their tumor's specific mutation profile — ELI-002 7P is an off-the-shelf product, a characteristic that simplifies manufacturing and reduces cost.

Elicio said it is currently evaluating multiple strategic financing and partnership options to support further development of the program.